CAR T-cell Therapy Market Insights, 2021-2031

CAR T-cell Therapy Market (Product Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, and Others; Indication: Acute Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, and Others; and End-user: Hospitals and Cancer Treatment Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Continuity in Provision of Medical Products Gains Importance During COVID-19 Outbreak

The coronavirus outbreak has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. Decline in people transit, closing of borders, and confinement of the population has impacted the supply chains of these life-saving medical products. This is anticipated to slowdown the growth of the CAR T-cell therapy market during the ongoing pandemic.

Although hospitals have been compelled to change their usual workflows to cope with the saturation of health services by hospitalized patients, stakeholders in the CAR T-cell therapy market are increasing efforts to ensure continuity in offering the treatment. This is prominent in the case of patients with relapsed/refractory hematologic malignancies. Moreover, the burgeoning growth of telehealth services is encouraging early intervention to attenuate neurotoxicity or cytokine release syndrome with tocilizumab and prophylactic/preventive strategies to prevent infection.

car t-cell therapy market infographic

Request a sample to get extensive insights into the CAR T-cell Therapy Market

Stakeholders Employ Innovative CAR Engineering Strategies to Improve Treatment Efficacy

The CAR T-cell therapy market is expected to clock a CAGR of 30.6% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses. However, market stakeholders need to address major limitations to the CAR T-cell therapy, which involves life-threatening CAR T-cell associated toxicities, limited persistence, and issues such as low efficacy against solid tumors. Hence, stakeholders are increasing their research capabilities to combine the CAR T-cell therapy with other anticancer therapies.

Stakeholders in the CAR T-cell therapy market are anticipated to collaborate with researchers, scientists, and biotechnologists to employ innovative CAR engineering strategies in order to improve anti-tumor efficacy, expand clinical efficacy, and limit toxicities. Stakeholders are increasing efforts to improve clinical efficacy in both hematological malignancy and solid tumors to overcome treatment limitations.

To understand how our report can bring difference to your business strategy, Ask for a brochure

In Vivo Gene Delivery to Immune Cells Shows Potential to Improve Medical Outcomes

Several hundred clinical trials of CAR-T have been registered and actively recruiting patients with various malignant & non-malignant conditions are showing rapid pace of innovation in this field. However, substantial challenges currently limit its widespread adoption. The CAR T-cell therapy is potentially expensive with both tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in the U.S. when used for high-grade B-cell lymphomas. Hence, stakeholders in the CAR T-cell therapy market are increasing efforts to reduce cost in order to meet the expanding indications of CAR-T.

Publically funded healthcare systems where resource allocation is strained, healthcare providers are striving to reduce treatment cost for CAR-T. Companies in the CAR T-cell therapy market are gaining awareness about novel strategies such as in vivo gene delivery to immune cells using nanoparticles to improve medical outcomes.

Stringent Regulations for Manufacturing CAR T-Cells Ensure Patient Safety

The CAR T-cell therapy market is projected to mature from a revenue of US$ 1.1 Bn in 2020 and reach US$ 21.8 Bn by 2031. From regulatory point of view, CAR T-cells are an advanced therapy medicinal product (ATMP) in the European Union (EU). Companies are increasing the availability of tissue-engineered products, gene therapy medicinal products, and somatic cell therapy medicinal products, among others. Such products are playing a crucial role in the treatment of cancer and hereditary diseases as well as in regenerative medicine.

CAR T-cells as an ATMP can be generated by either viral transduction, leading to a permanent CAR expression or by using mRNA. Companies in the CAR T-cell therapy market are increasing R&D investments in this field of the study. Manufacturing, approvals, and regulations of these therapies are potentially complex to protect patients.

Immunotherapy Helps in Treatment of New and Difficult Cancer Indications

The immunotherapy industry is an ever-evolving landscape with interest in CAR T-cells, checkpoint inhibitors, and bispecific antibodies exploding in the recent years. Likewise, Ceylad Oncology - a clinical stage biotechnology company, is gaining recognition for increasing its focus on CAR T-cell therapies, which involve engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen receptor binding. Such innovations are helping healthcare providers to treat new and difficult cancer indications, including solid tumors, and harness the immune system in a novel way to target new pathways.

Companies in the CAR T-cell therapy market are mainly focusing on immunotherapies that are showing potential in standalone treatments and in administration in combination with other types of treatments.

BIRAC Acquires Recognition for Increasing Availability of CAR T-cell Therapy in India

The CAR T-cell therapy is emerging as a breakthrough innovation in cancer treatment. Clinical trials conducted globally are showing promising results in end stage patients and especially, for patients suffering from Acute Lymphocytic Leukemia. Such findings are translating into revenue opportunities for companies in the CAR T-cell therapy market. However, there is a need to increase the availability of CAR T-cell therapy in India. A possible way to increase its availability in India is by reducing the cost of the treatment.

The manufacturing complexity is a major reason for high therapy cost in India. In order to promote and support the development of CAR T-cell technology against cancer and other diseases, the Biotechnology Industry Research Assistance Council (BIRAC) is taking the initiative to invite proposals in India.

Health and Research Policy Frameworks Promote Innovations in Treatment Options

Since medicine continues to be revolutionized by advancements in treatments, CAR T-cell therapies are achieving increased commercialization. Such trends are contributing to the growth of the global CAR T-cell therapy market. For instance, Anixa Biosciences, Inc. is being known for its therapeutics profile in a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T.

CAR T-cell therapies are subject to health and research policy frameworks as well as legal regulations that have a direct influence on international competitiveness. Companies in the CAR T-cell therapy market are adhering to this design framework, which is an important instrument to support research in the EU and to promote innovations. It has been found that there are strict regulations in Germany for the import of medicinal products in order to ensure patient safety.

car t-cell therapy market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on CAR T-cell Therapy Market

Analysts’ Viewpoint

Apart from gene therapy medicinal products, CAR T-cells holds promising potentials in the development of therapies for viral infections such as coronavirus. However, the high cost of CAR T-cell therapy in India is affecting market growth. Hence, companies in the India CAR T-cell therapy market should work closely with BIRAC and the Department of Biotechnology (DBT) to develop this technology in a cost effective manner whilst making it increasingly available for patients. The Tata Memorial Hospital (TMH), IIT Bombay team, and cancer care in India are gaining popularity for conducting the first CAR T-cell therapy at the bone marrow transplant unit at ACTREC, Tata Memorial Center in Mumbai.

CAR T-cell Therapy Market: Overview

  • Chimeric antigen receptors (CAR) are genetically engineered protein constructs that can be incorporated into a patient’s own cytotoxic T cells to help them to recognize and fight cancer cells
  • CAR T-cell therapy is used in the treatment of acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others
  • Increase in incidence of cancer and strong product pipeline are projected to drive the global CAR T-cell therapy market
  • Increase in incidence of cancer is likely to boost the growth of the global CAR T-cell therapy market during the forecast period. Cancer is a leading cause of death across the world. Majority of cancer cases are caused due to lifestyle-related factors such as alcohol consumption, tobacco consumption, and some food-related factors such as nitrites and polyaromatic hydrocarbons. According to World Health Organization statistics, in 2020, an estimated 19.3 million new cases of cancer and 10.0 million deaths were reported across the globe.
  • Major market players focus on research & development to develop new CAR T-cell therapy products for treatment of different types of cancer. This is another major factor fueling the growth of the global CAR T-cell therapy market. Majority of CAR T clinical researches focus on hematological cancer (57%), followed by CNS (8%), GI (6%), skin (5%), genitourinary (4%), breast (4%), gynecologic (4%), respiratory (3%), sarcoma (2%), mesothelioma (2%), and others (5%).

Market Segmentation: CAR T-cell Therapy Market

  • In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others
  • Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others
  • In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers
  • Each of the segments has been analyzed in detail for CAR T-cell therapy trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The CAR T-cell therapy market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: CAR T-cell Therapy Market

  • In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America accounted for the largest share of the global CAR T-cell therapy market in 2020 and the trend is projected to continue during the forecast period. Growth of the CAR T-cell therapy market in North America can be primarily ascribed to presence of major players, significant healthcare expenditure, early availability of new techniques, and increase in research activities across the country.
  • Asia Pacific is anticipated to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are expected to propel the CAR T-cell therapy market in the region.
  • The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the global CAR T-cell therapy market
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

CAR T-cell Therapy Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 1.1 Bn

Market Forecast Value in 2031

US$ 21.8 Bn

Growth Rate (CAGR)

30.6%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, parent industry overview, etc.

Competition Landscape

Company Profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, key financials, etc.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Axicabtagene Ciloleucel
    • Tisagenlecleucel
    • Brexucabtagene Autoleucel
    • Lisocabtagene Maraleucel
    • Idecabtagene Vicleucel
    • Others
  • Indication
    • Acute Lymphocytic Leukemia
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Others
  • End-user
    • Hospitals
    • Cancer Treatment Centers

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Novartis AG
  • Bristol-Myers Squibb
  • Amgen, Inc.
  • Sorrento Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • bluebird bio, Inc.
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

CAR T-cell Therapy Market – Segmentation

TMR’s study on the global CAR T-cell therapy market includes information divided into four segments: product type, indication, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global CAR T-cell therapy market are discussed in detail.

Product Type
  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleucel
  • Idecabtagene Vicleucel
  • Others
Indication
  • Acute Lymphocytic Leukemia
  • Diffuse Large B-cell lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Others
End-user
  • Hospitals
  • Cancer Treatment Centers
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of CAR T-cell therapy market?

CAR T-cell therapy market to reach valuation Of US$ 21.8 Bn by 2031

What is the anticipated CAGR of the CAR T-cell therapy market in the forecast period?

CAR T-cell therapy market is expected to clock a CAGR of 30.6% from 2021 to 2031

What are the key driving factors for the growth of the CAR T-cell therapy market?

CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline

Which region is expected to project the highest market share in the CAR T-cell therapy market?

North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period

Who are the key players in the CAR T-cell therapy market?

Key players operating in the global market include Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.

    1. Preface

        1.1. Report Scope and Market Segmentation

        1.2. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Assumptions and Acronyms Used

        2.2. Research Methodology

    3. Executive Summary

    4. Market Overview

        4.1. Introduction

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunity

        4.3. Global CAR T-cell Therapy Market Forecast

        4.4. Global CAR T-cell Therapy Market Outlook

    5. Market Outlook

        5.1. Key Industry Events

        5.2. Diseases Epidemiology

        5.3. Product Pipeline Analysis

        5.4. Impact of COVID-19 Pandemic

    6. Global CAR T-cell Therapy Market Analysis, by Product Type

        6.1. Introduction

        6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type

        6.3. Global CAR T-cell Therapy Market Forecast, by Product Type

            6.3.1. Axicabtagene Ciloleucel

            6.3.2. Tisagenlecleucel

            6.3.3. Brexucabtagene Autoleucel

            6.3.4. Lisocabtagene Maraleucel

            6.3.5. Idecabtagene Vicleucel

            6.3.6. Others

        6.4. Global CAR T-cell Therapy Market Analysis, by Product Type

        6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type

    7. Global CAR T-cell Therapy Market Analysis, by Indications

        7.1. Introduction

        7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication

        7.3. Global CAR T-cell Therapy Market Forecast, by Indication

            7.3.1. Acute Lymphocytic Leukemia

            7.3.2. Diffuse Large B-Cell Lymphoma

            7.3.3. Follicular Lymphoma

            7.3.4. Mantle Cell Lymphoma

            7.3.5. Multiple Myeloma

            7.3.6. Others

        7.4. Global CAR T-cell Therapy Market Analysis, by Indication

        7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication

    8. Global CAR T-cell Therapy Market Analysis, by End-user

        8.1. Introduction

        8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user

        8.3. Global CAR T-cell Therapy Market Forecast, by End-user

            8.3.1. Hospitals

            8.3.2. Cancer Treatment Centers

        8.4. Global CAR T-cell Therapy Market Analysis, by End-user

        8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user

    9. Global CAR T-cell Therapy Market Analysis, by Region

        9.1. Global CAR T-cell Therapy Market Analysis, by Region

        9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region

        9.3. Global CAR T-cell Therapy Market Forecast, by Region

            9.3.1. North America

            9.3.2. Europe

            9.3.3. Asia Pacific

            9.3.4. Latin America

            9.3.5. Middle East & Africa

    10. North America CAR T-cell Therapy Market Analysis

        10.1. North America CAR T-cell Therapy Market Overview

        10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country

        10.3. North America CAR T-cell Therapy Market Forecast, by Country

            10.3.1. U.S.

            10.3.2. Canada

        10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

        10.5. North America CAR T-cell Therapy Market Forecast, by Product Type

            10.5.1. Axicabtagene Ciloleucel

            10.5.2. Tisagenlecleucel

            10.5.3. Brexucabtagene Autoleucel

            10.5.4. Lisocabtagene Maraleucel

            10.5.5. Idecabtagene Vicleucel

            10.5.6. Others

        10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications

        10.7. North America CAR T-cell Therapy Market Forecast, by Indication

            10.7.1. Acute Lymphocytic Leukemia

            10.7.2. Diffuse Large B-Cell Lymphoma

            10.7.3. Follicular Lymphoma

            10.7.4. Mantle Cell Lymphoma

            10.7.5. Multiple Myeloma

            10.7.6. Others

        10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

        10.9. North America CAR T-cell Therapy Market Forecast, by End-user

            10.9.1. Hospitals

            10.9.2. Cancer Treatment Centers

    11. Europe CAR T-cell Therapy Market Analysis

        11.1. Europe CAR T-cell Therapy Market Overview

        11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

        11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region

            11.3.1. Germany

            11.3.2. France

            11.3.3. U.K.

            11.3.4. Italy

            11.3.5. Spain

            11.3.6. Rest of Europe

        11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

        11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type

            11.5.1. Axicabtagene Ciloleucel

            11.5.2. Tisagenlecleucel

            11.5.3. Brexucabtagene Autoleucel

            11.5.4. Lisocabtagene Maraleucel

            11.5.5. Idecabtagene Vicleucel

            11.5.6. Others

        11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

        11.7. Europe CAR T-cell Therapy Market Forecast, by Indication

            11.7.1. Acute Lymphocytic Leukemia

            11.7.2. Diffuse Large B-Cell Lymphoma

            11.7.3. Follicular Lymphoma

            11.7.4. Mantle Cell Lymphoma

            11.7.5. Multiple Myeloma

            11.7.6. Others

        11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

        11.9. Europe CAR T-cell Therapy Market Forecast, by End-user

            11.9.1. Hospitals

            11.9.2. Cancer Treatment Centers

    12. Asia Pacific CAR T-cell Therapy Market Analysis

        12.1. Asia Pacific CAR T-cell Therapy Market Overview

        12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

        12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region

            12.3.1. China

            12.3.2. Japan

            12.3.3. India

            12.3.4. Australia & New Zealand

            12.3.5. Rest of Asia Pacific

        12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

        12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type

            12.5.1. Axicabtagene Ciloleucel

            12.5.2. Tisagenlecleucel

            12.5.3. Brexucabtagene Autoleucel

            12.5.4. Lisocabtagene Maraleucel

            12.5.5. Idecabtagene Vicleucel

            12.5.6. Others

        12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

        12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication

            12.7.1. Acute Lymphocytic Leukemia

            12.7.2. Diffuse Large B-Cell Lymphoma

            12.7.3. Follicular Lymphoma

            12.7.4. Mantle Cell Lymphoma

            12.7.5. Multiple Myeloma

            12.7.6. Others

        12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

        12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user

            12.9.1. Hospitals

            12.9.2. Cancer Treatment Centers

    13. Latin America CAR T-cell Therapy Market Analysis

        13.1. Latin America CAR T-cell Therapy Market Overview

        13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

        13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region

            13.3.1. Brazil

            13.3.2. Mexico

            13.3.3. Rest of Latin America

        13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

        13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type

            13.5.1. Axicabtagene Ciloleucel

            13.5.2. Tisagenlecleucel

            13.5.3. Brexucabtagene Autoleucel

            13.5.4. Lisocabtagene Maraleucel

            13.5.5. Idecabtagene Vicleucel

            13.5.6. Others

        13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

        13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication

            13.7.1. Acute Lymphocytic Leukemia

            13.7.2. Diffuse Large B-Cell Lymphoma

            13.7.3. Follicular Lymphoma

            13.7.4. Mantle Cell Lymphoma

            13.7.5. Multiple Myeloma

            13.7.6. Others

        13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

        13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user

            13.9.1. Hospitals

            13.9.2. Cancer Treatment Centers

    14. Middle East & Africa CAR T-cell Therapy Market Analysis

        14.1. Middle East & Africa CAR T-cell Therapy Market Overview

        14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

        14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region

            14.3.1. GCC Countries

            14.3.2. South Africa

            14.3.3. Rest of Middle East & Africa

        14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

        14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type

            14.5.1. Axicabtagene Ciloleucel

            14.5.2. Tisagenlecleucel

            14.5.3. Brexucabtagene Autoleucel

            14.5.4. Lisocabtagene Maraleucel

            14.5.5. Idecabtagene Vicleucel

            14.5.6. Others

        14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

        14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication

            14.7.1. Acute Lymphocytic Leukemia

            14.7.2. Diffuse Large B-Cell Lymphoma

            14.7.3. Follicular Lymphoma

            14.7.4. Mantle Cell Lymphoma

            14.7.5. Multiple Myeloma

            14.7.6. Others

        14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

        14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user

            14.9.1. Hospitals

            14.9.2. Cancer Treatment Centers

    15. Competition Landscape

        15.1. Competition Matrix

        15.2. Company Profiles

            15.2.1. Pfizer Inc.

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Product Portfolio

                15.2.1.3. Financial Overview

                15.2.1.4. SWOT Analysis

                15.2.1.5. Strategic Overview

            15.2.2. Novartis AG

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Product Portfolio

                15.2.2.3. Financial Overview

                15.2.2.4. SWOT Analysis

                15.2.2.5. Strategic Overview

            15.2.3. Bristol-Myers Squibb

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Product Portfolio

                15.2.3.3. Financial Overview

                15.2.3.4. SWOT Analysis

                15.2.3.5. Strategic Overview

            15.2.4. Amgen, Inc.

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Product Portfolio

                15.2.4.3. Financial Overview

                15.2.4.4. SWOT Analysis

                15.2.4.5. Strategic Overview

            15.2.5. Sorrento Therapeutics, Inc.

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Product Portfolio

                15.2.5.3. Financial Overview

                15.2.5.4. SWOT Analysis

                15.2.5.5. Strategic Overview

            15.2.6. Johnson & Johnson Services, Inc.

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Product Portfolio

                15.2.6.3. Financial Overview

                15.2.6.4. SWOT Analysis

                15.2.6.5. Strategic Overview

            15.2.7. Gilead Sciences, Inc.

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.7.2. Product Portfolio

                15.2.7.3. Financial Overview

                15.2.7.4. SWOT Analysis

                15.2.7.5. Strategic Overview

            15.2.8. Merck & Co., Inc.

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Product Portfolio

                15.2.8.3. Financial Overview

                15.2.8.4. SWOT Analysis

                15.2.8.5. Strategic Overview

            15.2.9. bluebird bio, Inc.

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Product Portfolio

                15.2.9.3. Financial Overview

                15.2.9.4. SWOT Analysis

                15.2.9.5. Strategic Overview

    List of Tables

    Table 01: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 02: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 03: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 07: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 08: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 11: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 12: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 15: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 16: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 17: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 19: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 20: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 23: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 24: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global CAR T-cell Therapy Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global CAR T-cell Therapy Market Value Share, by Product Type, 2020

    Figure 03: Global CAR T-cell Therapy Market Value Share, by Indication, 2020

    Figure 04: Global CAR T-cell Therapy Market Value Share, by End-user Type, 2020

    Figure 05: Global CAR T-cell Therapy Market Value Share, by Region, 2020

    Figure 06: Global Car T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 07: Global Car T-Cell Therapy Market Value (US$ Mn), by Axicabtagene Ciloleucel, 2017–2031

    Figure 08: Global Car T-Cell Therapy Market Value (US$ Mn), by Tisagenlecleucel, 2017–2031

    Figure 09: Global Car T-Cell Therapy Market Value (US$ Mn), by Brexucabtagene Autoleucel, 2017–2031

    Figure 10: Global Car T-Cell Therapy Market Value (US$ Mn), by Lisocabtagene Maraleucel, 2017–2031

    Figure 11: Global Car T-Cell Therapy Market Value (US$ Mn), by Idecabtagene Vicleucel, 2017–2031

    Figure 12: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031

    Figure 13: Global Car T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 14: Global Car T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 15: Global Car T-Cell Therapy Market Value (US$ Mn), by Acute Lymphocytic Leukemia, 2017–2031

    Figure 16: Global Car T-Cell Therapy Market Value (US$ Mn), by Diffuse Large B-cell Lymphoma, 2017–2031

    Figure 17: Global Car T-Cell Therapy Market Value (US$ Mn), by Follicular Lymphoma, 2017–2031

    Figure 18: Global Car T-Cell Therapy Market Value (US$ Mn), by Mantle Cell Lymphoma, 2017–2031

    Figure 19: Global Car T-Cell Therapy Market Value (US$ Mn), by Multiple Myeloma, 2017–2031

    Figure 20: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031

    Figure 21: Global Car T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 22: Global Car T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 23: Global Car T-Cell Therapy Market Value (US$ Mn), by Hospitals, 2017–2031

    Figure 24: Global Car T-Cell Therapy Market Value (US$ Mn), by Cancer Treatment Centers, 2017–2031

    Figure 25: Global Car T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 26: Global Car T-Cell Therapy Market Value Share Analysis, by Region, 2020 and 2031

    Figure 27: Global Car T-Cell Therapy Market Attractiveness Analysis, by Region, 2021-2031

    Figure 28: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 29: North America CAR T-Cell Therapy Market Value Share (%), by Country, 2020 and 2031

    Figure 30: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Country, 2021–2031

    Figure 31: North America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 32: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 33: North America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 34: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 35: North America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 36: North America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 37: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 38: Europe CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 39: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 40: Europe CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 41: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 42: Europe CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 43: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 44: Europe CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 45: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 46: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 47: Asia Pacific CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 48: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 49: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 50: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 51: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 52: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 53: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 54: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 55: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 56: Latin America CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 57: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 58: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 59: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 60: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 61: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 62: Latin America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 63: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 64: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 65: Middle East & Africa CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 66: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 67: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 68: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 69: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

    Figure 70: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

    Figure 71: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 72: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 73: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 74: Pfizer, Inc., Breakdown of Net Sales (%), by Biopharma Segment, 2020

    Figure 75: Pfizer, Inc., Breakdown of Net Sales (%) Region/Country, 2020

    Figure 76: Pfizer, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 77: Novartis AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 78: Novartis AG, Revenue Breakdown of Net Sales (%), by Business Segment, 202

    Figure 79: Novartis AG, Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 80: Novartis AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 81: Bristol-Myers Squibb, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020

    Figure 82: Bristol-Myers Squibb, Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 83: Bristol-Myers Squibb, R&D Expenses (US$ Mn) 2017–2020

    Figure 84: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 85: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 86: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 87: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 88: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 89: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 90: Johnson & Johnson Services, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 91: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Business Segment (Pharmaceutical), 2020

    Figure 92: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 93: Johnson & Johnson Services, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

    Figure 94: Gilead Sciences, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 95: Gilead Sciences, Inc., Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 96: Gilead Sciences, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

    Figure 97: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 98: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 99: Merck & Co., Inc., Breakdown of Net Sales (%), by Region/Country, 2020

    Figure 100: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

    Figure 101: bluebird bio, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

    Figure 102: bluebird bio, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

Copyright © Transparency Market Research, Inc. All Rights reserved